Developing innovative solutions to improve outcomes for patients with cancer
Developing innovative solutions to improve outcomes for patients with cancer
AccuStem in the news
AccuStem in the news
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
London, UK and Phoenix, AZ (April 28, 2022)- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences [...]
AccuStem Announces DTC Eligibility
London, UK and Phoenix, AZ (April 14, 2022)- AccuStem Sciences, Inc. (OTCQB: ACUT), a life [...]
AccuStem Announces Private Placement of Common Stock
London, UK and Phoenix, AZ (April 5, 2022)- AccuStem Sciences, Inc. (OTC Pink: ACUT), a [...]
AccuStem will take a holistic approach to the oncology space.
Our vision is to develop diagnostics, therapeutics and other technologies under one umbrella to offer a more integrated solution for physicians and their patients.
We are currently building a novel genomic test for use across a broad spectrum of tumor types. Click here to learn more about StemPrint.
